Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.

Best practice & research. Clinical endocrinology & metabolism - 1 Jun 2014

Chan Dick C, Barrett P Hugh R, Watts Gerald F

Abstract excerpt

Dyslipoproteinaemia is a cardinal feature of the metabolic syndrome that accelerates atherosclerosis. It is characterized by high plasma concentrations of triglyceride-rich and apolipoprotein (apo) B-containing lipoproteins, with depressed high-density lipoprotein (HDL) and increased small dense low-density lipoprotein (LDL) particle concentrations. Dysregulation of lipoprotein metabolism in the metabolic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diet
Share to Dyslipidemias
Share to Atherosclerosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hypolipidemic Agents

Share to Life Style

Share to Lipoproteins

Share to Metabolic Syndrome

Source

Identifiers

PMID: 24840265
DOI: 10.1016/j.beem.2013.10.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.PMID 24840265Read ↗

Advances in biological therapies for dyslipidemias and atherosclerosisSemantic proximity Read ↗

Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype.Semantic proximity Read ↗

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Semantic proximity Read ↗

Novel and future lipid-modulating therapies for the prevention of cardiovascular diseaseSemantic proximity Read ↗

Sex aspects in lipoprotein metabolism, dyslipidemia, and lipid-lowering therapy: A comprehensive reviewSemantic proximity Read ↗

National Lipid Association Annual Summary of Clinical Lipidology 2015.Semantic proximity Read ↗

Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy.Semantic proximity Read ↗

"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses.Semantic proximity Read ↗

Treating low HDL--from bench to bedside.Semantic proximity Read ↗

A new dawn for managing dyslipidemias: The era of rna-based therapiesSemantic proximity Read ↗

Hyperlipidemia as a risk factor for cardiovascular disease.Semantic proximity Read ↗

[Lipoprotein metabolism disorders. II. Epidemiology, classification, and diagnosis].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.